Form 4: Guardant Health Chief Commercial Officer Reports Routine Equity Transactions

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations, alongside an Employee Stock Purchase Plan acquisition.

Summary

• Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported multiple transactions on June 15, 2025, related to his beneficial ownership.
• He acquired a total of 6,281 shares of common stock (4,879 shares and 1,402 shares) through the vesting and exercise of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 2,675 shares were disposed of at a price of $49.29 to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Freeman's direct beneficial ownership of common stock stands at 46,757 shares.
• The filing also noted the acquisition of 859 shares under Guardant Health's Employee Stock Purchase Plan (ESPP) on May 14, 2025, which is included in the reported beneficial ownership.
• One RSU award, from which 4,879 shares vested, completed its vesting schedule on June 15, 2025, with 25% vesting on June 15, 2022, and the remainder in equal installments over three years.
• Another RSU award, granted on June 9, 2023, saw 1,402 shares vest on June 15, 2025, as part of its three-year vesting schedule (33% vested on June 15, 2024, with the remaining 67% vesting quarterly over two years).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transactions are routine compensation events, indicating continued executive retention and alignment. The disposition of shares is for tax purposes, not a discretionary sale, which is a positive sign of commitment.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the continued retention and incentivization of a key executive, Chris Freeman, aligning his interests with shareholders.
• The acquisition of 859 shares through the Employee Stock Purchase Plan (ESPP) demonstrates the Chief Commercial Officer's personal investment and confidence in Guardant Health's stock.

Negatives

• A portion of the vested shares (2,675 shares) was disposed of to cover tax withholding obligations, which reduces the executive's direct shareholding.

Risks

• The disposition of shares for tax withholding, while routine, could be misinterpreted by some investors as a sale, potentially leading to minor, short-term negative sentiment if not understood as a standard compensation practice.

Future Outlook

The document indicates future vesting installments for the remaining 5,608 Restricted Stock Units, which are set to vest in equal quarterly installments over the remaining two-year period after June 15, 2024.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, specifically related to executive compensation through equity awards. It reflects standard practices in the biotechnology and healthcare diagnostics industry where equity incentives are a common component of executive remuneration, aligning management interests with long-term company performance.

Stakeholder Impact

• Shareholders: Provides transparency into executive equity ownership and compensation practices. The routine nature of the transactions suggests stability in executive incentives.
• Employees: Reinforces the company's commitment to equity-based compensation plans, potentially boosting morale and retention.

Next Steps

• Continued vesting of the remaining 5,608 Restricted Stock Units in equal quarterly installments over the next two years.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, insider trading, Restricted Stock Units, RSU vesting, stock compensation, tax withholding, Chris Freeman, Chief Commercial Officer, employee stock purchase plan